Received Nov 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
a patient got a First dose of the SHINGRIX vaccine at their facility on November ninth and received a Second dose on November twenty first on a different location; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 28-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on 09-NOV-2025, expiry date 16-Sep-2026). On 21-NOV-2025, the patient received the 2nd dose of Shingrix. On 21-NOV-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: a patient got a First dose of the SHINGRIX vaccine at their facility on November ninth and received a Second dose on November twenty first on a different location). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 24-NOV-2025 Patient got a first dose of the Shingrix vaccine at their facility on November ninth Patient received a Second dose on November twenty first on a different location. The batch number was not provided and a request for this information has been made.